QUALITY ASSURANCE & PERFORMANCE IMPROVEMENT Clause Samples
The QUALITY ASSURANCE & PERFORMANCE IMPROVEMENT clause establishes the requirement for ongoing evaluation and enhancement of the quality and effectiveness of services or products provided under the agreement. Typically, this clause mandates that the party responsible must implement systematic processes to monitor performance, identify areas for improvement, and take corrective actions as needed—such as conducting regular audits or reviews. Its core function is to ensure that standards are consistently met or exceeded, thereby reducing the risk of subpar outcomes and promoting continuous improvement throughout the contract term.
QUALITY ASSURANCE & PERFORMANCE IMPROVEMENT. 1. The State will develop and implement a quality assurance and performance improvement monitoring system to ensure that community-based placements and services are developed in accordance with this Agreement, and that the individuals who receive services or Housing Slots pursuant to this Agreement are provided with the services and supports they need for their health, safety, and welfare. The goal of the State’s system will be that all mental health and other services and supports funded by the State are of good quality and are sufficient to help individuals achieve increased independence, gain greater integration into the community, obtain and maintain stable housing, avoid ▇▇▇▇▇, and decrease the incidence of hospital contacts and institutionalization.
2. A Transition Oversight Committee will be created at DHHS to monitor monthly progress of implementation of this Agreement, and will be chaired by the DHHS Designee (Deputy Secretary). The Division of Medical Assistance, Division of Mental Health, Developmental Disabilities, and Substance Abuse Services, Division of State Operated Healthcare Facilities, State Hospital Team Lead, State Hospital Chief Executive Officers, Money Follows the Person Program, and PIHPs and/or LMEs will be responsible for reporting on the progress being made. PIHPs and/or LMEs will be responsible for reporting on discharge-related measures, including, but not limited to: housing vacancies; discharge planning and transition process; referral process and subsequent admissions; time between application for services to discharge destination; and actual admission date to community-based settings.
3. DHHS agrees to take the following steps related to Quality Assurance and Performance Improvement:
a. Develop and phase in protocols, data collection instruments and database enhancements for on-going monitoring and evaluation;
b. Develop and implement uniform application for institutional census tracking;
c. Develop and implement standard report to monitor institutional patients length of stay, readmissions and community tenure;
d. Develop and implement dashboard for daily decision support;
e. Develop and implement centralized housing data system to inform discharge planning;
f. Develop and utilize template for published, annual progress reports;
g. Develop and utilize monitoring and evaluation protocols and data collection regarding personal outcomes measures, which include the following:
i. number of incidents of harm
ii. number of repe...
QUALITY ASSURANCE & PERFORMANCE IMPROVEMENT. A. Required, ongoing, continuing education (CE) of 30 hours per year is required.
1. Each Pharmacist Provider will have their education file and documentation of training maintained in their non-official personnel file
2. Contents may be submitted to the Quality Assurance director and/or Clinical Director upon request
▇. ▇▇▇▇ and FPPE processes will be conducted consistent with Medical staff bylaws.
1. Minimum of four OPPE’s quarterly.
2. Using the Peer Review Checklist for that specified disease state
3. Upon request for any hospitalizations, sentinel events, death, etc.
C. Clinic outcome evaluation should be done at least annually. This shall be reported to the local Pharmacy & Therapeutics Committee and the National Clinical Pharmacy Specialists Committee (NCPSC). Data may be collected from RPMS, iCARE, and ISTAR to evaluate: patient satisfaction, DUE data, reported incidents, patient outcomes, and other data points as needed. General outcomes reported should include, but not limited to:
1. GPRA data
2. Clinical outcome results to include, but not limited to, those required by NCPSC
3. De-prescribing results
D. If a Pharmacist Provider is unable to meet or exceed the national or IHS standard goals of a disease state, additional training and/or review may be required until performance is deemed acceptable or privileges revoked by the Pharmacy Director and/or MEC.
E. Peer reviews and clinical outcomes will be reported annually to the Pharmacy Primary care clinic manager and the Pharmacy Director to review for performance improvement.